Skip to main content

Smith + Nephew Plc Value Stock - Dividend - Research Selection

Smith and nephew

ISIN: GB0009223206 , WKN: 502816

Market price date:
Market price:  


Fundamental data and company key figures of the share

Annual reports in
Key figures
Cash flow
Net operating cash flow
Capital Expenditures
Free cash flow
Balance sheet
Total Equity
Liabilities & Shareholders equity
Income statement
Net income
Eps (diluted)
Diluted shares outstanding
Net sales/revenue

Fundamental ratios calculated on:

Ratios
Key figures
Cash flow
P/C
 
P/FC
Balance sheet
ROI
ROE
Income statement
P/E
Div. Yield %
P/B
P/S


Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
Fundamental data up to 25 years
Comparison to all other stocks by the FScore
Time saving!

How our site works ...

Non-binding 7 days without automatic subscription
 No termination required after the free week
Finanzoo fundamental analysis
Data updated daily
Virtual depots
Share alarms via email
Subscription can be canceled at any time at the end of the month 
Choice of desired shares
Over 2000 stock analyzes available
Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.



Description Data
Symbol
Market Capitalization USD
Country
Indices
Sectors
Raw Data Source
Stock Split
Internet


Description of the company

Smith & Nephew plc designs, develops, and sells medical devices worldwide. The company offers sports medicine joint repair products for surgeons, including an array of instruments, technologies, and implants necessary to perform minimally invasive surgery of the joints, such as the repair of soft tissue injuries and degenerative conditions of the knee, hip, and shoulder. It also provides arthroscopic enabling technologies for healthcare providers comprising fluid management equipment for surgical access, high definition cameras, digital image capture, scopes, light sources, and monitors to assist with visualization inside the joints, radio frequency, electromechanical and mechanical tissue resection devices, and hand instruments for removing damaged tissue. In addition, the company offers trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures; robotics-assisted surgery, various products, and technologies to assist in surgical treatment of the ear, nose, and throat; knee implant products for specialized knee replacement procedures; and hip implant products for the reconstruction of hip joints. Further, it provides advanced wound care products for the treatment and prevention of acute and chronic wounds, which comprise leg, diabetic and pressure ulcers, burns, and post-operative wounds; advanced wound bioactives, including biologics and other bioactive technologies for debridement and dermal repair/regeneration; and advanced wound devices, such as traditional and single-use negative pressure wound therapy and hydrosurgery systems. The company primarily serves the providers of medical and surgical treatments and services. Smith & Nephew plc was founded in 1856 and is headquartered in London, the United Kingdom.

The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources:: www.bundesanzeiger.de, www.sec.gov,


NEWS


Smith+Nephew extends Advanced Wound Bioactives portfolio with US launch of CENTRIO Platelet-Rich-Plasma System

2025-09-03
Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, today announces the launch of the CENTRIO Platelet-Rich-Plasma (PRP) System, a biodynamic hematogel derived from a patient’s own platelets and plasma that, once applied, may assist the natural healing process by maintaining a moist wound environment. CENTRIO PRP System can help manage chronic exuding wounds including but not limited to diabetic foot ulcers (DFUs), venous leg ulcers (VLUs), pressure ulcers, and tunnelling wou

Are Investors Undervaluing Smith & Nephew SNATS (SNN) Right Now?

2025-09-02
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

SNN or SYK: Which Is the Better Value Stock Right Now?

2025-09-02
SNN vs. SYK: Which Stock Is the Better Value Option?

We Like These Underlying Return On Capital Trends At Smith & Nephew (LON:SN.)

2025-08-29
If we want to find a potential multi-bagger, often there are underlying trends that can provide clues. Ideally, a...

SNN vs. SYK: Which Stock Is the Better Value Option?

2025-08-15
SNN vs. SYK: Which Stock Is the Better Value Option?

Statutory Profit Doesn't Reflect How Good Smith & Nephew's (LON:SN.) Earnings Are

2025-08-12
LSE:SN. 1 Year Share Price vs Fair Value Explore Smith & Nephew's Fair Values from the Community and select yours Smith...

BP fuels FTSE 100 but soft US data tempers gains

2025-08-05
The FTSE 100 Index closed up 14.43 points at 9,142.73.

European Equities Traded in the US as American Depositary Receipts Lower in Tuesday Trading

2025-08-05
European equities traded in the US as American depositary receipts were lower late Tuesday morning,

Smith & Nephew plc 2025 Q2 - Results - Earnings Call Presentation

2025-08-05
The following slide deck was published by Smith & Nephew plc in conjunction with their 2025 Q2 earnings call.

Smith & Nephew plc (SNN) Q2 2025 Earnings Call Transcript

2025-08-05
Smith & Nephew plc (NYSE:SNN) Q2 2025 Earnings Conference Call August 5, 2025 3:30 AM ETCompany ParticipantsDeepak S.